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Background: This study investigated the overall status of diabetes control and screening for diabetic microvascular complications in 
patients with type 2 diabetes mellitus attending primary care clinics in Korea. 
Methods: In this cross-sectional observational study, 191 primary care clinics were randomly selected across Korea from 2015 to 
2016. In total, 3,227 subjects were enrolled in the study. 
Results: The patients followed at the primary care clinics were relatively young, with a mean age of 61.4±11.7 years, and had a rel-
atively short duration of diabetes (mean duration, 7.6±6.5 years). Approximately 14% of subjects had diabetic microvascular com-
plications. However, the patients treated at the primary care clinics had suboptimal control of hemoglobin A1c levels, blood pressure, 
and serum lipid levels, along with a metabolic target achievement rate of 5.9% according to the Korean Diabetes Association guide-
lines. The screening rates for diabetic nephropathy, retinopathy, and neuropathy within the past 12 months were 28.4%, 23.3%, and 
13.3%, respectively.
Conclusion: The overall status of diabetes management, including the frequency of screening for microvascular complications, was 
suboptimal in the primary care clinics. More efforts should be made and more resources need to be allocated for primary care physi-
cians to promote adequate healthcare delivery, which would result in stricter diabetes control and improved management of diabetic 
complications. 
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INTRODUCTION
The prevalence of type 2 diabetes mellitus (T2DM) continues to 
rise and is projected to increase to 592 million in 2035 world-
wide [1,2]. Unfortunately, Korea is not an exception; the preva-
lence of diabetes is steadily increasing and a recent study re-
vealed that about 4.8 million Korean adults (13.7%) have diabe-
tes [3]. Both microvascular and macrovascular complications 
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develop quite commonly in patients with diabetes, and cause 
significant morbidity and mortality [4,5]. 
Trials investigating diabetes control and complications have 
shown that intensive glycemic treatment effectively delays the 
onset and progression of diabetic microvascular complications 
in type 1 diabetes [6], and similar findings were noted in patients 
with T2DM [7], with benefits extending beyond the period of in-
tervention [8,9]. Despite strong evidence of the benefits of tight 
glycemic control, an analysis of data from the 2014 Korea Na-
tional Health and Nutrition Examination Survey (KNHANES) 
indicated that more than 50% of adults diagnosed with diabetes 
in Korea failed to achieve a hemoglobin A1c (HbA1c) level be-
low 7%, a result similar to that found in the USA [10,11]. A few 
studies have demonstrated that the overall diabetes management 
in patients who attended primary care clinics was less optimal 
than that of patients followed at secondary or tertiary hospitals 
[12-14], but there is a paucity of data comparing primary care to 
secondary or tertiary care following the release of the Korean 
Diabetes Association (KDA) clinical practice guidelines. 
In response to the increasing prevalence of non-communica-
ble diseases (NCDs), the Korean government introduced a clin-
ic-centered NCD management policy in 2012, which focused 
on strengthening the role of primary care clinics as an important 
source of outpatient care for NCDs [15]. According to the 
Health Insurance Review & Assessment Service, approximately 
60% of patients with diabetes visited primary care clinics for 
management of diabetes in 2017 [16]; however, very few stud-
ies have examined the rate of adherence to the KDA guidelines 
in primary care clinics. The primary aim of this study was to ex-
amine the current status of overall diabetes management, in-
cluding the screening rate for microvascular complications, 
among patients with T2DM visiting primary care clinics. The 
secondary aim was to compare the findings from primary care 
clinics to those from two tertiary hospitals in Seoul. 
METHODS
Study design and population 
A total of 191 primary care clinics were randomly selected 
across Korea, from which 2,915 patients with T2DM were en-
rolled in this study from January 2015 to September 2016 (Fig. 
1). To maximize the generalizability of the results, the subjects 
were selected by random sampling from 16 cities and provinces 
(seven special and metropolitan cities including Seoul, Busan, 
Daegu, Incheon, Gwangju, Daejeon, and Ulsan) and nine prov-
inces (Gyeonggi-do, Gangwon-do, Chungcheongbuk-do, Chun-
gcheongnam-do, Jeollabuk-do, Jeollanam-do, Gyeongsangbuk-
do, Gyeongsangnam-do, and Jeju provinces) across Korea. The 
regional distribution of the enrollees was similar to that of the 
entire Korean population, as in the 2017 Korean Population 
Census [17]. As a secondary objective of our study, we com-
pared primary care clinics with tertiary hospitals by analyzing 
3,227 Potentially eligible
Primary care clinics
(191 clinics with a total of 2,915 patients
287 Initial visit
2,625 Follow-up visit
(3 unclassified visit)
0 Initial visit
312 Follow-up visit
Tertiary hospitals
(2 hospitals with 312 patients)
Inclusion criteria
-Age ≥19 years
-Diagnosed with type 2 diabetes
-Able to consent
Exclusion criteria
-Age <19 years
-Type 1 diabetes
Fig. 1. Flowchart of the patients enrolled in the study. 
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data from 312 patients with T2DM who attended tertiary hospi-
tals for diabetes management, at Severance Hospital in the 
northern part of Seoul and Gangnam Severance Hospital in the 
southern part of Seoul (the total number of outpatient visits for 
diabetes management per year are 30,879 patients/year and 
16,155 patients/year at Severance Hospital and Gangnam Sev-
erance Hospital, respectively). Among all patients who met both 
inclusion and exclusion criteria, those who consented were en-
rolled in the study consecutively. The inclusion criteria of the 
study were patients with T2DM who were ≥19 years old and 
were willing to provide consent. Patients with type 1 diabetes 
and patients who were <19 years old were excluded. A diagno-
sis of type 1 diabetes were made if one of the following condi-
tions was present; fasting C-peptide ≤0.6 ng/mL, postprandial 
2-hour C-peptide ≤1.8 ng/mL, anti- glutamic acid decarboxyl-
ase antibody positivity, anti-insulin antibody positivity, or anti-
islet cell antibody positivity. Atherosclerotic cardiovascular dis-
ease (ASCVD) was defined as a previous history of stroke, 
ischemic heart disease, or peripheral vascular disease. Data, in-
cluding laboratory assessments, were collected on the day of the 
outpatient clinic visit and were recorded in a pre-formulated 
case report by the physicians. The study protocol was approved 
by the Institutional Review Board of Severance Hospital, and 
written informed consent was obtained from all participants 
(IRB no. 4-2014-0904 and IRB no. 3-2014-0270). 
Anthropometric and biochemical measurements
Data collected from the patients included demographic charac-
teristics, past medical history, duration of diabetes, smoking his-
tory, as well as any history of diabetic vascular complications 
within the 12 months before enrollment. The treatment modali-
ties of diabetes were classified as diet only, oral hypoglycemic 
agents (OHAs) alone, insulin alone, or a combination of insulin 
and OHAs. For those who were current smokers or had any his-
tory of smoking, data on whether they were ever offered smok-
ing cessation intervention during previous encounters with the 
physicians were also gathered. 
Each patient’s height, weight, waist circumference, and blood 
pressure (BP) were measured and participants were also asked 
about the date and modality of BP measurements (i.e., digital 
method or analog method). Hypertension was defined as a BP 
≥140/90 mm Hg or taking antihypertensive medication(s). 
Data on when the laboratory assessments were done were also 
collected, as well as the types of blood tests (capillary or plasma 
blood test) and the frequency and type of glycemic assessments 
(fasting glucose, random glucose, or HbA1c). To evaluate dys-
lipidemia, data were collected on the types of lipid tests (total 
lipid panel or partial lipid profile) in the 12 months before enroll-
ment. Screening for microvascular complications was consid-
ered to have been done if there were records of any of the fol-
lowing: fundus eye exam, spot urine test for albumin-to-creati-
nine ratio or 24-hour urine test, monofilament test, pinprick test, 
ankle reflex test, nerve conduction test, or a referral to a special-
ist within the previous 12 to 24 months. Microalbuminuria and 
overt proteinuria were defined as a random urine albumin-to-
creatinine ratio between 30 and 300 mg/g and above 300 mg/g, 
respectively. The prevalence of retinopathy, nephropathy, neu-
ropathy, ischemic heart disease, cerebrovascular disease, and pe-
ripheral artery disease was investigated based on the patient’s 
past medical history. The optimal targets were defined as HbA1c 
<6.5% for blood glucose, <140/85 mm Hg for BP, and low den-
sity lipoprotein cholesterol (LDL-C) <100 mg/dL for the blood 
lipid profile [18]. For those with ASCVD, BP <130/80 mm Hg 
and serum LDL-C <70 mg/dL were defined as the optimal tar-
gets according to the KDA treatment guideline for diabetes 2019 
[18]. 
Statistical analysis
We used SPSS version 20.0 (IBM Corp., Armonk, NY, USA) 
for the statistical analysis and considered P values <0.05 to in-
dicate statistical significance. Continuous variables with a nor-
mal distribution were presented as mean±standard deviation 
(SD), and categorical variables as absolute numbers (percentag-
es). The Student t test, chi-square test, and Fisher exact test were 
used to test the statistical significance of differences between 
mean values.
RESULTS
General characteristics and diabetes control status of the 
study population 
The mean age of the subjects in the primary care setting was 
61.4±11.7 years and the mean duration of diabetes was 7.6±
6.5 years, with a mean HbA1c of 7.6%±2.0%. Approximately 
two-thirds of the patients had concomitant hypertension and 
dyslipidemia, with suboptimal control of blood glucose, serum 
lipids, and BP (Table 1). The prevalence of diabetic microvas-
cular and macrovascular complications were 13.7% and 14.4%, 
respectively (Table 1). Among the 2,915 patients with T2DM 
followed at primary care clinics, the majority of the patients 
were treated with OHAs (96%) and the most frequently pre-
scribed OHA was metformin (84%), followed by dipeptidyl 
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Table 1. General Characteristics of the Study Population
Characteristic Primary (n=2,915) Tertiary (n=312) P value
Age, yr 61.4±11.7 63.4±11.0 0.004a
Male sex 1,612 (55.3) 189 (60.6) 0.075
Age at diabetes diagnosis, yr 53.8±11.3 53.3±10.9 0.484
Duration of diabetes, yr 7.6±6.5 10.1±8.7 <0.0001a
Visit type
   Initial visit 287 (9.9) 0 <0.0001a
   Follow-up visit 2,625 (90.1) 312 (100.0) <0.0001a
BMI, kg/m2 25.1±3.4 25.3±3.3 0.377
   Male 25.2±3.2 25.2±3.4 0.957
   Female 25.0±3.7 25.4±3.1 0.184
Weight, kg 67.5±12.1 67.8±11.6 0.673
   Male 72.8±11.1 72.0±11.0 0.397
   Female 60.8±9.7 61.2±9.1 0.712
WC, cm 86.6±9.6 88.5±8.2 0.100
   Male 88.6±8.7 89.0±9.6 0.600
   Female 83.8±10.1 85.3±9.0 0.140
Hypertension 1,718 (58.9) 160 (51.4) 0.011a
Dyslipidemia 1,736 (59.6) 181 (58.2) 0.644
SBP, mm Hg 128.3±12.9 121.5±12.7 <0.0001a
DBP, mm Hg 78.2±8.9 73.4±9.7 <0.0001a
HbA1c, % 7.6±2.0 6.9±0.9 <0.0001a
Fasting glucose, mg/dL 145.9±56.1 127.4±28.0 <0.0001a
Total cholesterol, mg/dL 177.2±41.8 157.0±31.3 <0.0001a
TG, mg/dL 166.4±102.1 136.9±104.2 <0.0001a
HDL-C, mg/dL 48.3±13.0 47.5±11.5 0.265
LDL-C, mg/dL 98.3±34.8 83.2±26.3 <0.0001a
Creatinine, mg/dL 1.2± 4.4 0.9±0.4 0.002a
UACR, mg/g 80.0±332.1 68.7±298.5 0.597
Current smoker 603 (20.7) 37 (11.9) <0.0001a
Smoking cessation interventionb 772 (84.6) 68 (43.0) <0.0001a
Microvascular complicationsc 399 (13.7) 79 (25.4) <0.0001a
   Diabetic retinopathy 132 (4.5) 49 (15.8) <0.0001a
   Diabetic nephropathy 141 (4.8) 28 (9.0) 0.002a
   Diabetic neuropathy 171 (5.9) 27 (8.7) 0.049a
Macrovascular complicationsc 421 (14.4) 58 (18.6) 0.050
OHA alone 2,695 (92.5) 278 (89.1) 0.037a
   Monotherapyd  670 (24.9) 116 (41.7) <0.0001a
   Dual therapyd 1,361 (50.5) 124 (44.6) 0.008a
   Triple therapyd 692 (25.7) 64 (23.0) 0.145
OHA (alone or with insulin) 2,795 (95.9) 305 (97.8) 0.106
Insulin 114 (3.9) 29 (9.3) <0.0001a
   Insulin alonee 14 (12.3) 2 (6.9) 0.527
   Insulin with OHAe 100 (87.7) 27 (93.1) 0.527
No medication 106 (3.6) 5 (1.6) 0.061
Values are expressed as mean±standard deviation or number (%). P values refer to the unpaired t test or the chi-square test. 
BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c; hemoglobin A1c; TG, triglyceride; HDL-
C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; UACR, urinary albumin-to-creatinine ratio; OHA, oral hypoglycemic agent. 
aValues with statistical significance; bThe denominator is the total number of current smokers and those who had a history of smoking after the diagnosis of diabe-
tes; cExcludes those with multiple choices/answers; dThe denominator is the number of people taking OHAs only; eThe denominator is the total number of people 
taking insulin with or without OHAs. 
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peptidase 4 (DPP4) inhibitors (65%) and sulfonylureas (41%) 
(Supplemental Table S1). The proportion of the patients pre-
scribed OHAs was significantly higher than the insulin prescrip-
tion rate of 4% (Table 1).
Screening rate for diabetic microvascular complications 
and metabolic target achievement rate
The overall prevalence of diabetic complications was signifi-
cantly lower among the patients treated at primary care clinics 
than among those treated at tertiary hospitals (Table 1). The 
screening rates for diabetic retinopathy, nephropathy, and neu-
ropathy within the past 12 months were 23%, 28%, and 13%, 
respectively, at primary care clinics (Table 2, Fig. 2). In other 
words, more than two-thirds of patients did not receive any 
screening tests in a year. Moreover, the proportion of the pa-
tients who achieved optimal metabolic targets (HbA1c, BP, and 
LDL-C) was only 5.9% among those followed at primary care 
clinics (Table 3). In a sub-analysis of those with ASCVD, the 
proportion of subjects who achieved the optimal BP and lipid 
profile targets (BP <130/80 mm Hg and LDL-C <70 mg/dL) 
was 26.4% and 16.6%, respectively (Supplemental Table S2).
Table 2. Screening for Diabetic Microvascular Complications
Variable Primary (n=2,915)
Tertiary 
(n=312)
Diabetic retinopathy
   Within 12 mo 679 (23.3) 155 (49.7)
   12–24 mo 114 (3.9) 37 (11.9)
   Referral for screening tests within 24 mo 114 (3.9) 0
   No tests within 24 mo 2,008 (68.9) 120 (38.5)
Diabetic nephropathy
   Within 12 mo 828 (28.4) 274 (87.8)
   12–24 mo 77 (2.6) 10 (3.2)
   Referral for screening tests within 24 mo 32 (1.1) 0
   No tests within 24 mo 1,977 (67.8) 28 (9.0)
Diabetic neuropathy
   Within 12 mo 388 (13.3) 122 (39.1)
   12–24 mo 43 (1.5) 17 (5.4)
   Referral for screening tests within 24 mo 44 (1.5) 0
   No tests within 24 mo 2,440 (83.7) 173 (55.4)
Values are expressed as number (%).
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Fig. 2. Comparison of the screening done for microvascular com-
plications at primary care clinics versus the tertiary hospitals. aRe-
ferral for screening tests within 24 months.
Table 3. Metabolic Target Achievement Rate
Variable Primary (n=2,915)
Tertiary 
(n=312)
P value
Glycemic control
   HbA1c <6.5%b 501 (22.5) 105 (34.4) <0.0001a
   HbA1c <7.0%b 934 (41.9) 193 (63.3) <0.0001a
BP control
   BP <140/85 mm Hg 1,913 (65.6) 257 (82.4) <0.0001a
   BP <140/90 mm Hg 2,057 (70.6) 307 (98.4) <0.0001a
Dyslipidemia control
   LDL-C <100 mg/dLc 1,132 (55.7) 239 (78.6) <0.0001a
   HDL-C ≥40 mg/dLd 1,645 (73.8) 224 (73.4) 0.884
   TG <150 mg/dLe 1,290 (54.5) 216 (70.6) <0.0001a
Three metabolic targetsf,g 172 (5.9) 67 (21.5) <0.0001a
Values are expressed as number (%). P values refer to the chi-square 
test. 
HbA1c, hemoglobin A1c; BP, blood pressure; LDL-C, low density lipo-
protein cholesterol; HDL-C, high density lipoprotein cholesterol; TG, 
triglyceride.
aValues with statistical significance; bThe denominator is the number of 
people who had HbA1c testing within 3 months prior to enrollment 
(n=2,224); cThe denominator is the number of people who had LDL-C 
testing within 12 months prior to enrollment (n=2,031); dThe denomi-
nator is the number of people who had HDL-C testing within 12 months 
prior to enrollment (n=2,228); eThe denominator is the number of peo-
ple who had TG testing within 12 months prior to enrollment 
(n=2,366); fThe denominator is the total number of subjects in each 
group; gThree metabolic targets: HbA1c <6.5%, BP <140/85 mm Hg, 
and LDL-C <100 mg/dL. 
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Frequency and method of glucose, BP, and cholesterol 
monitoring
Although 95% of the subjects had at least one form of glycemic 
assessment (random glucose testing, fasting glucose testing, or 
HbA1c test), HbA1c testing was significantly underutilized at 
primary care clinics. Furthermore, two-thirds of the patients fol-
lowed at primary care clinics only received HbA1c tests one to 
two times per year (Table 4). 
For BP monitoring, 94% of the subjects had BP measurements 
taken on the day of their encounter at a primary care clinic, and 
the analog method was still preferred to assess BP. For lipid pro-
file tests, the proportion of the subjects who had a total lipid 
panel test was significantly less at primary care clinics (Table 4). 
Smoking status and counseling
Among the subjects who attended the primary care clinics, 
20.7% were current smokers, and the majority of current smok-
ers were offered smoking cessation education or counseling.
 
DISCUSSION
This study investigated the overall status of diabetes manage-
ment in 2,915 patients with T2DM treated at primary care clin-
ics in Korea, and found that most of the patients did not meet 
Table 4. Frequency and Method of Tests for Diabetes Management
Variable Primary  (n=2,915) Tertiary  (n=312) P value
Glycemic testsa 2,743 (94.1) 311 (99.7) <0.001b
   Fasting glucose testc,d 1,504 (54.9) 311 (100.0) <0.001b
      Plasma blood samplinge 756 (50.3) 311 (100.0)
      POCTe 819 (54.5) 0 
   Random glucose testc,d 1,638 (59.7) 20 (6.4) <0.001b
      Plasma blood samplingf 297 (18.1) 20 (100.0)
      POCTf 1,352 (82.5) 0 
   HbA1c testc,d 1,507 (55.0) 302 (97.1) <0.001b
      Plasma blood samplingg 1,117 (74.1) 302 (100.0)
      POCTg 391 (25.9) 0 
No. of HbA1c tests within 12 months <0.0001b
   None 191 (6.6) 1 (0.3)
   1–2 times/yr 1,866 (64.0) 38 (12.2)
   ≥3 times/yr 706 (24.2) 273 (87.5)
   Did not know 101 (3.5) 0 
Performing BP monitoringh 2,720 (93.3) 311 (99.7) <0.0001b
   Analog methodi 1,726 (63.5) 0 
   Digital methodi 1,006 (37.0) 311 (100.0)
Performing lipid profile testj 2,907 (99.7) 312 (100.0) <0.0001b
   Total lipid panelk   1,783 (61.3) 304 (97.4)
   Partial lipid testk (partial)  696 (23.9) 8 (2.6)
   No lipid panel testk 244 (8.4) 0 
Values are expressed as number (%). P values refer to the chi-square test. 
POCT, point of care test; HbA1c, hemoglobin A1c; BP, blood pressure.
aFor glycemic control, patients were asked if they had blood tests on the day of the visit; bValues with statistical significance; cThe denominator is the 
number of subjects who received a fasting glucose test; dIncludes those with multiple choices/answers; eThe denominator is the number of subjects who 
received a fasting glucose test; fThe denominator is the number of subjects who received a random glucose test; gThe denominator is the number of sub-
jects who received a HbA1c test; hFor BP monitoring, patients were asked if they had a BP measurement on the day of the visit; iThe denominator is the 
number of subjects who received BP monitoring on the day of visit; jFor the lipid profile test, patients attending an initial visit were asked if they had a 
blood test for their lipid profile on the day of the visit and patients attending a follow-up visit were asked if they had a blood test for their lipid profile 
within 12 months; kThe denominator is the number of subjects who received lipid profile tests within 12 months.
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the current clinical practice guidelines recommended by the 
KDA. Only approximately 22.5% of the patients achieved the 
recommended level of glycemic control. These findings agree 
with those of previous studies of primary care settings that 
showed a high frequency of poor glycemic control [12]. Our 
data also demonstrate that a low proportion of patients received 
screening tests for microvascular complications, which clearly 
demonstrates a deficiency in the management of diabetes. 
Hence, more efforts and suitable measures need to be intro-
duced to improve the care provided to patients with diabetes at 
primary care clinics in Korea.
The prevalence of T2DM and its complications continues to 
rise [10,19,20]. In order to prevent diabetic microvascular and 
macrovascular complications, comprehensive management of 
diabetes is crucial. Despite the development of numerous new 
antidiabetic medications, the proportion of patients achieving 
target glycemic control (HbA1c <7% defined by the American 
Diabetes Association [ADA] guidelines) has plateaued in the 
United States since 2006 [11]. In Korea, the proportion of the 
patients achieving optimal glycemic control (i.e., HbA1c <7%,) 
continued to improve from 42.5% in 2005 to 44.9% in 2014 
[10]; however, this proportion was significantly lower for pa-
tients treated at primary care clinics than for those treated at ter-
tiary hospitals in our study (41.9% vs. 63.3%, P<0.0001). In 
other words, a large proportion of patients are still at a high risk 
of developing diabetic complications, particularly those who at-
tend the primary care clinics.
There have been significant changes in the prescription pat-
terns of antidiabetic medications following the introduction of 
DPP4 inhibitors in 2008. In 2002, sulfonylureas were the most 
commonly used antidiabetic medications for T2DM patients; 
however, the prescription rate for metformin has steadily in-
creased, and metformin has been the most frequently prescribed 
antidiabetic drug since 2013, followed by sulfonylureas and 
then DPP4 inhibitors [19]. These changes are clearly reflected 
in the prescription patterns found in our study, where the most 
commonly prescribed dual combination was metformin and a 
DPP4 inhibitor. DPP4 inhibitors are readily used by many 
healthcare providers, including primary care physicians, be-
cause of their ease of use, fair glycemic control, neutral effect 
on body weight, and low hypoglycemia rate. However, the pro-
portion of the subjects prescribed insulin was very low at pri-
mary care clinics. This may be partly due to the introduction of 
various antidiabetic agents, including DPP4 inhibitors, and a 
shortage of educational staff with expertise on insulin therapy at 
primary care clinics [12].
Both ADA and KDA guidelines recommend monitoring 
HbA1c at least biannually in patients with stable glycemic con-
trol and quarterly in patients who do not meet their treatment 
goals or who have changed medication [18,21]. Despite steady 
improvements in the frequency of HbA1c monitoring since the 
introduction of a diabetes care quality assurance program [16], 
those managed at primary care clinics were infrequently tested 
for HbA1c [22]. Furthermore, consistent with previous reports 
[16,22], random glucose testing using a portable glucometer 
was the most commonly used method for glycemic monitoring, 
most likely because of the lack of laboratory facilities at primary 
care clinics. This indicates that poor diabetes control in patients 
treated at primary care clinics may be related to less intensive 
and less frequent monitoring, despite shorter visit intervals.
Despite the recommendations on annual screening for diabet-
ic microvascular complications contained in the KDA guideline 
[18], the screening rates for diabetic retinopathy, nephropathy, 
and neuropathy at primary care clinics were quite low. Previous 
studies have suggested that a lack of resources, such as limited 
access to facilities for screening tests for complications, and pa-
tients’ socioeconomic status were associated with the frequency 
of diabetic screening tests [23-25]. Similar findings were also 
noted in the Pittsburgh Epidemiology of Diabetes Complica-
tions study, in which it was found that receiving care from pri-
mary care physicians, instead of from diabetes specialists, was 
associated with lower preventive service utilization and poorer 
glycemic control [26]. Physicians’ attitudes toward caring for 
diabetic patients can be another barrier, as some primary care 
physicians felt that the guidelines for reaching the goals were 
not clear and relied on their clinical experience when making 
decisions to screen [24,27]. Moreover, they often faced admin-
istrative, time, and information constraints [27]. As preventive 
health care is the cornerstone of the primary and secondary pre-
vention of diabetes complications, improving diabetes educa-
tion for both patients and providers in primary care settings and 
establishing a system that allows easy referrals to specialists 
may improve the utilization of preventive services.
Moreover, a systemic program or a policy needs to be imple-
mented by the government in order to improve and sustain the 
comprehensive management of diabetes at primary care clinics. 
It is necessary to introduce a compensation system based on the 
health outcomes of patients to encourage primary care physi-
cians to participate more actively in the management of diabe-
tes. For example, the introduction of non-monetary compensa-
tion systems, such as the Green Prescription Clinics, for clinics 
with excellent target achievement rates can drive voluntary 
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quality improvement of primary care clinics.
There are some limitations of this study. First, this was a 
cross-sectional observational study, which did not allow us to 
monitor changes over time. Second, a total of 312 patients from 
two tertiary hospitals were enrolled for this study and used as 
comparators. However, the tertiary hospitals may have been pri-
marily representative of the Gangbuk and Gangnam areas, 
whereas the primary endpoint of this study was to examine the 
current status of T2DM management at primary care clinics. 
Nevertheless, this is the first study to examine the current status 
of diabetes management in Koreans, especially with a focus on 
the frequency and method of follow-up tests and screenings for 
microvascular complications at primary care clinics.
In conclusion, despite steady improvements over the past de-
cade, we found that the overall status of diabetes management, 
including the screening rates for complications, was still subop-
timal in patients with T2DM who attended primary care clinics. 
Substantially more efforts and resources need to be deployed for 
primary physicians to improve their adherence to clinical prac-
tice guidelines and to deliver the most optimal healthcare in the 
primary care setting. 
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